{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T22:33:38Z","timestamp":1793572418355,"version":"4.5.0"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T00:00:00Z","timestamp":1761523200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T00:00:00Z","timestamp":1761523200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-17627-5","type":"journal-article","created":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T13:34:40Z","timestamp":1761572080000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Real-world FAERS safety analysis of Pralsetinib"],"prefix":"10.1038","volume":"15","author":[{"given":"Dongdong","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yixin","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peiji","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengfu","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,27]]},"reference":[{"issue":"4","key":"17627_CR1","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.4143\/crt.2023.403","volume":"55","author":"Y Jeon","year":"2023","unstructured":"Jeon, Y. et al. Expanded access program Pralsetinib in advanced Non-Small cell lung cancer with rearranged during transfection (RET) gene rearrangement. Cancer Res. Treat. 55 (4), 1144\u20131151 (2023).","journal-title":"Cancer Res. Treat."},{"issue":"20","key":"17627_CR2","doi-asserted-by":"publisher","first-page":"5452","DOI":"10.1158\/1078-0432.CCR-21-0967","volume":"27","author":"J Kim","year":"2021","unstructured":"Kim, J. et al. FDA approval summary: Pralsetinib for the treatment of lung and thyroid cancers with RET gene mutations or fusions. Clin. Cancer Res. 27 (20), 5452\u20135456 (2021).","journal-title":"Clin. Cancer Res."},{"issue":"15","key":"17627_CR3","doi-asserted-by":"publisher","first-page":"E42","DOI":"10.1200\/JCO.23.00281","volume":"41","author":"N Singh","year":"2023","unstructured":"Singh, N. et al. Therapy for stage IV Non-Small-Cell lung cancer with driver alterations: ASCO living guideline, version 2023.1. J. Clin. Oncol. 41 (15), E42\u2013E50 (2023).","journal-title":"J. Clin. Oncol."},{"issue":"5","key":"17627_CR4","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1007\/s12272-022-01385-3","volume":"45","author":"F Ali","year":"2022","unstructured":"Ali, F., Neha, K. & Chauhan, G. Pralsetinib: chemical and therapeutic development with FDA authorization for the management of RET fusion-positive non-small-cell lung cancers. Arch. Pharm. Res. 45 (5), 309\u2013327 (2022).","journal-title":"Arch. Pharm. Res."},{"issue":"31","key":"17627_CR5","doi-asserted-by":"publisher","first-page":"3166","DOI":"10.1111\/1759-7714.15105","volume":"14","author":"X Pu","year":"2023","unstructured":"Pu, X. et al. Expert consensus on the diagnosis and treatment of RET gene fusion non-small cell lung cancer in China. Thorac. Cancer. 14 (31), 3166\u20133177 (2023).","journal-title":"Thorac. Cancer"},{"key":"17627_CR6","first-page":"27","volume":"10","author":"G Bronte","year":"2019","unstructured":"Bronte, G. et al. Targeting RET-rearranged non-small-cell lung cancer: future prospects. Lung Cancer (Auckland NZ). 10, 27\u201336 (2019).","journal-title":"Lung Cancer (Auckland NZ)"},{"key":"17627_CR7","doi-asserted-by":"crossref","unstructured":"Gainor, J. F. et al. Registrational dataset from the phase I\/II ARROW trial of Pralsetinib (BLU-667) in patients (pts) with advanced RET fusion plus non-small cell lung cancer (NSCLC). J. Clin. Oncol. ;38(15). (2020).","DOI":"10.1200\/JCO.2020.38.15_suppl.9515"},{"issue":"9","key":"17627_CR8","doi-asserted-by":"publisher","first-page":"2874","DOI":"10.21037\/gs-21-469","volume":"10","author":"J Ma","year":"2021","unstructured":"Ma, J., Wang, B. S., Meng, E. H. & Meng, X. P. Case report: identification of ERC1-RET fusion in a patient with pancreatic ductal adenocarcinoma. Gland Surg. 10 (9), 2874\u20132879 (2021).","journal-title":"Gland Surg."},{"issue":"7","key":"17627_CR9","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1016\/S1470-2045(21)00247-3","volume":"22","author":"JF Gainor","year":"2021","unstructured":"Gainor, J. F. et al. Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1\/2 study. Lancet Oncol. 22 (7), 959\u2013969 (2021).","journal-title":"Lancet Oncol."},{"issue":"17","key":"17627_CR10","first-page":"1865","volume":"80","author":"A Markham","year":"2020","unstructured":"Markham, A. & Pralsetinib First Approval Drugs ;80(17):1865\u20131870. (2020).","journal-title":"First Approval Drugs"},{"key":"17627_CR11","doi-asserted-by":"crossref","unstructured":"Li, A. Y. et al. RET fusions in solid tumors. Cancer Treat. Rev. ;81. (2019).","DOI":"10.1016\/j.ctrv.2019.101911"},{"issue":"2","key":"17627_CR12","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/j.annonc.2020.10.599","volume":"32","author":"V Subbiah","year":"2021","unstructured":"Subbiah, V. et al. Structural basis of acquired resistance to Selpercatinib and Pralsetinib mediated by non-gatekeeper RET mutations. Ann. Oncol. 32 (2), 261\u2013268 (2021).","journal-title":"Ann. Oncol."},{"issue":"11","key":"17627_CR13","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1200\/JCO.19.02551","volume":"38","author":"V Subbiah","year":"2020","unstructured":"Subbiah, V., Yang, D., Velcheti, V., Drilon, A. & Meric-Bernstam, F. State-of-the-Art strategies for targeting RET-Dependent cancers. J. Clin. Oncol. 38 (11), 1209\u2013 (2020).","journal-title":"J. Clin. Oncol."},{"issue":"5","key":"17627_CR14","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.1111\/j.1475-6773.2011.01269.x","volume":"46","author":"U Sarkar","year":"2011","unstructured":"Sarkar, U., Lopez, A., Maselli, J. H. & Gonzales, R. Adverse drug events in U.S. Adult ambulatory medical care. Health Serv. Res. 46 (5), 1517\u20131533 (2011).","journal-title":"Health Serv. Res."},{"issue":"12","key":"17627_CR15","doi-asserted-by":"publisher","first-page":"101332","DOI":"10.1016\/j.xcrm.2023.101332","volume":"4","author":"M Nardo","year":"2023","unstructured":"Nardo, M. et al. Strategies for mitigating adverse events related to selective RET inhibitors in patients with RET-altered cancers. Cell. Rep. Med. 4 (12), 101332 (2023).","journal-title":"Cell. Rep. Med."},{"issue":"12","key":"17627_CR16","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.1016\/S1470-2045(16)30562-9","volume":"17","author":"A Drilon","year":"2016","unstructured":"Drilon, A. et al. Cabozantinib in patients with advanced RET-rearranged non-small-cell lung cancer: an open-label, single-centre, phase 2, single-arm trial. Lancet Oncol. 17 (12), 1653\u20131660 (2016).","journal-title":"Lancet Oncol."},{"key":"17627_CR17","doi-asserted-by":"crossref","unstructured":"Shu, Y., Chen, J., Ding, Y. & Zhang, Q. Adverse events with Risankizumab in the real world: postmarketing pharmacovigilance assessment of the FDA adverse event reporting system. Front. Immunol. ;14. (2023).","DOI":"10.3389\/fimmu.2023.1169735"},{"issue":"7","key":"17627_CR18","doi-asserted-by":"publisher","first-page":"623","DOI":"10.2165\/00002018-200730070-00011","volume":"30","author":"A Bate","year":"2007","unstructured":"Bate, A. Bayesian confidence propagation neural network. Drug Saf. 30 (7), 623\u2013625 (2007).","journal-title":"Drug Saf."},{"issue":"3","key":"17627_CR19","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1080\/00031305.1999.10474456","volume":"53","author":"W DuMouchel","year":"1999","unstructured":"DuMouchel, W. Bayesian data mining in large frequency tables, with an application to the FDA spontaneous reporting system. Am. Stat. 53 (3), 177\u2013190 (1999).","journal-title":"Am. Stat."},{"issue":"8","key":"17627_CR20","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1002\/pds.1001","volume":"13","author":"KJ Rothman","year":"2004","unstructured":"Rothman, K. J., Lanes, S. & Sacks, S. T. The reporting odds ratio and its advantages over the proportional reporting ratio. Pharmacoepidemiol. Drug Saf. 13 (8), 519\u2013523 (2004).","journal-title":"Pharmacoepidemiol. Drug Saf."},{"issue":"6","key":"17627_CR21","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1038\/clpt.2013.24","volume":"93","author":"R Harpaz","year":"2013","unstructured":"Harpaz, R. et al. Performance of pharmacovigilance Signal-Detection algorithms for the FDA adverse event reporting system. Clin. Pharmacol. Ther. 93 (6), 539\u2013546 (2013).","journal-title":"Clin. Pharmacol. Ther."},{"key":"17627_CR22","doi-asserted-by":"crossref","unstructured":"Raschi, E., Fusaroli, M., Ardizzoni, A., Poluzzi, E. & De Ponti, F. Thromboembolic events with Cyclin-Dependent kinase 4\/6 inhibitors in the FDA adverse event reporting system. Cancers ;13(8). (2021).","DOI":"10.3390\/cancers13081758"},{"issue":"4","key":"17627_CR23","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1016\/S2213-8587(22)00035-3","volume":"10","author":"M Pizzato","year":"2022","unstructured":"Pizzato, M. et al. The epidemiological landscape of thyroid cancer worldwide: GLOBOCAN estimates for incidence and mortality rates in 2020. Lancet Diabetes Endocrinol. 10 (4), 264\u2013272 (2022).","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"9","key":"17627_CR24","doi-asserted-by":"publisher","first-page":"2187","DOI":"10.1002\/ijc.29251","volume":"136","author":"C La Vecchia","year":"2015","unstructured":"La Vecchia, C. et al. Thyroid cancer mortality and incidence: A global overview. Int. J. Cancer. 136 (9), 2187\u20132195 (2015).","journal-title":"Int. J. Cancer"},{"key":"17627_CR25","doi-asserted-by":"crossref","unstructured":"Hess, L. M., Han, Y., Zhu, Y. E., Bhandari, N. R. & Sireci, A. Characteristics and outcomes of patients with RET-fusion positive non-small lung cancer in real-world practice in the united States. Bmc Cancer ;21(1). (2021).","DOI":"10.1186\/s12885-020-07714-3"},{"issue":"5","key":"17627_CR26","doi-asserted-by":"publisher","first-page":"575","DOI":"10.3727\/096504018X15344979253618","volume":"27","author":"K Zhang","year":"2019","unstructured":"Zhang, K. et al. Clinical characteristics and molecular patterns of RET-Rearranged lung cancer in Chinese patients. Oncol. Res. 27 (5), 575\u2013582 (2019).","journal-title":"Oncol. Res."},{"issue":"4","key":"17627_CR27","doi-asserted-by":"publisher","first-page":"617","DOI":"10.21037\/tlcr-22-202","volume":"11","author":"J Feng","year":"2022","unstructured":"Feng, J. et al. Clinicopathologic characteristics and diagnostic methods of RET rearrangement in Chinese non-small cell lung cancer patients. Translational Lung Cancer Res. 11 (4), 617\u2013 (2022).","journal-title":"Translational Lung Cancer Res."},{"issue":"8","key":"17627_CR28","doi-asserted-by":"publisher","first-page":"1640","DOI":"10.1038\/s41591-022-01931-y","volume":"28","author":"V Subbiah","year":"2022","unstructured":"Subbiah, V. et al. Pan-cancer efficacy of Pralsetinib in patients with RET fusion-positive solid tumors from the phase 1\/2 ARROW trial. Nat. Med. 28 (8), 1640\u2013 (2022).","journal-title":"Nat. Med."},{"issue":"8","key":"17627_CR29","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/S2213-8587(21)00120-0","volume":"9","author":"V Subbiah","year":"2021","unstructured":"Subbiah, V. et al. Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1\/2 study. Lancet Diabetes Endocrinol. 9 (8), 491\u2013501 (2021).","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"11","key":"17627_CR30","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.1016\/j.annonc.2022.08.002","volume":"33","author":"F Griesinger","year":"2022","unstructured":"Griesinger, F. et al. Safety and efficacy of Pralsetinib in RET fusion-positive non-small-cell lung cancer including as first-line therapy: update from the ARROW trial. Ann. Oncol. 33 (11), 1168\u20131178 (2022).","journal-title":"Ann. Oncol."},{"issue":"1","key":"17627_CR31","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1021\/acs.chemrestox.9b00387","volume":"33","author":"SD Lamore","year":"2020","unstructured":"Lamore, S. D., Kohnken, R. A., Peters, M. F. & Kolaja, K. L. Cardiovascular toxicity induced by kinase inhibitors: mechanisms and preclinical approaches. Chem. Res. Toxicol. 33 (1), 125\u2013136 (2020).","journal-title":"Chem. Res. Toxicol."},{"issue":"8","key":"17627_CR32","doi-asserted-by":"publisher","first-page":"2130","DOI":"10.1158\/1078-0432.CCR-20-3558","volume":"27","author":"D Bradford","year":"2021","unstructured":"Bradford, D. et al. FDA approval summary: Selpercatinib for the treatment of lung and thyroid cancers with RET gene mutations or fusions. Clin. Cancer Res. 27 (8), 2130\u20132135 (2021).","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"17627_CR33","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1089\/thy.2022.0506","volume":"33","author":"KJ Contrera","year":"2023","unstructured":"Contrera, K. J. et al. Neoadjuvant selective RET inhibitor for medullary thyroid cancer: A case series. Thyroid 33 (1), 129\u2013132 (2023).","journal-title":"Thyroid"},{"issue":"10","key":"17627_CR34","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1200\/OP.22.00365","volume":"18","author":"IA Jaiyesimi","year":"2022","unstructured":"Jaiyesimi, I. A., Temin, S., Singh, N. & Panel, A. E. Therapy for stage IV Non-Small-Cell lung cancer with and without driver alterations: ASCO living guidelines Q and A. Jco Oncol. Pract. 18 (10), 699\u2013 (2022).","journal-title":"Jco Oncol. Pract."},{"issue":"6","key":"17627_CR35","first-page":"e15441","volume":"13","author":"A Papaila","year":"2021","unstructured":"Papaila, A. & Jacobson, A. T. Into the unknown: A case of New-Onset cardiomyopathy in a patient treated with recently approved tyrosine kinase inhibitor, Pralsetinib. Cureus 13 (6), e15441\u2013e (2021).","journal-title":"Cureus"},{"issue":"8","key":"17627_CR36","first-page":"E347","volume":"22","author":"JF Gainor","year":"2021","unstructured":"GainorJF et al. Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1\/2 study (22, Pg 959, 2021). Lancet Oncol. 22 (8), E347\u2013E (2021).","journal-title":"Lancet Oncol."},{"issue":"5","key":"17627_CR37","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1210\/endrev\/bnad013","volume":"44","author":"ML Gild","year":"2023","unstructured":"Gild, M. L., Clifton-Bligh, R. J., Wirth, L. J. & Robinson, B. G. Medullary thyroid cancer: updates and challenges. Endocr. Rev. 44 (5), 934\u2013946 (2023).","journal-title":"Endocr. Rev."},{"key":"17627_CR38","doi-asserted-by":"crossref","unstructured":"Kang, Y., Jin, Y., Li, Q. & Yuan, X. Advances in lung cancer driver genes associated with brain metastasis. Front. Oncol. ;10. (2021).","DOI":"10.3389\/fonc.2020.606300"},{"issue":"4","key":"17627_CR39","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1200\/JCO.2011.38.0527","volume":"30","author":"PW Sperduto","year":"2012","unstructured":"Sperduto, P. W. et al. Summary report on the graded prognostic assessment: an accurate and facile Diagnosis-Specific tool to estimate survival for patients with brain metastases. J. Clin. Oncol. 30 (4), 419\u2013425 (2012).","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"17627_CR40","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1159\/000535172","volume":"16","author":"LAW de Jong","year":"2023","unstructured":"de Jong, L. A. W., Sparidans, R. W. & van den Heuvel, M. M. Cerebrospinal fluid concentration of the RET inhibitor pralsetinib: A case report. Case Rep. Oncol. 16 (1), 1579\u20131585 (2023).","journal-title":"Case Rep. Oncol."},{"key":"17627_CR41","doi-asserted-by":"crossref","unstructured":"Senturk, R., Wang, Y., Schinkel, A. H., Beijnen, J. H. & Sparidans, R. W. Quantitative bioanalytical assay for the selective RET inhibitors Selpercatinib and Pralsetinib in mouse plasma and tissue homogenates using liquid chromatography-tandem mass spectrometry. J. Chromatogr. B-Analytical Technol. Biomedical Life Sci. ;1147. (2020).","DOI":"10.1016\/j.jchromb.2020.122131"},{"key":"17627_CR42","doi-asserted-by":"crossref","unstructured":"Subbiah, V. et al. Clinical activity of the RET inhibitor Pralsetinib (BLU-667) in patients with RET fusion-positive solid tumors. J. Clin. Oncol. ;39(3). (2021).","DOI":"10.1200\/JCO.2021.39.3_suppl.467"},{"key":"17627_CR43","doi-asserted-by":"crossref","unstructured":"Gao, M. et al. Pralsetinib-associated pneumonia in RET fusion-positive non-small cell lung cancer. Support. Care Cancer ;31(12). (2023).","DOI":"10.1007\/s00520-023-08125-3"},{"issue":"6","key":"17627_CR44","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1111\/bjh.13373","volume":"169","author":"SP Yajnanarayana","year":"2015","unstructured":"Yajnanarayana, S. P. et al. JAK1\/2 Inhibition impairs T cell function invitro and in patients with myeloproliferative neoplasms. Br. J. Haematol. 169 (6), 824\u2013833 (2015).","journal-title":"Br. J. Haematol."},{"issue":"2","key":"17627_CR45","doi-asserted-by":"publisher","first-page":"E193","DOI":"10.1016\/j.cllc.2020.10.001","volume":"22","author":"M Park","year":"2021","unstructured":"Park, M., Ho, D. Y., Wakelee, H. A. & Neal, J. W. Opportunistic invasive fungal infections mimicking progression of Non Small-Cell lung cancer. Clin. Lung Cancer. 22 (2), E193\u2013E200 (2021).","journal-title":"Clin. Lung Cancer"},{"key":"17627_CR46","doi-asserted-by":"crossref","unstructured":"Maschmeyer, G. et al. Infections associated with immunotherapeutic and molecular targeted agents in hematology and oncology. A position paper by the European Conference on Infections in Leukemia (ECIL). Leukemia. ;33(4):844\u2009\u2013\u200962. (2019).","DOI":"10.1038\/s41375-019-0388-x"},{"issue":"9","key":"17627_CR47","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1056\/NEJMoa2005653","volume":"383","author":"A Drilon","year":"2020","unstructured":"Drilon, A. et al. Efficacy of Selpercatinib in RET Fusion-Positive Non-Small-Cell lung cancer. N. Engl. J. Med. 383 (9), 813\u2013824 (2020).","journal-title":"N. Engl. J. Med."},{"issue":"13","key":"17627_CR48","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1200\/JCO.2016.70.9352","volume":"35","author":"O Gautschi","year":"2017","unstructured":"Gautschi, O. et al. Targeting RET in patients with RET-Rearranged lung cancers: results from the global, multicenter RET registry. J. Clin. Oncol. 35 (13), 1403\u2013 (2017).","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"17627_CR49","doi-asserted-by":"publisher","first-page":"218","DOI":"10.18553\/jmcp.2021.21308","volume":"28","author":"S Duff","year":"2022","unstructured":"Duff, S., Bargiacchi, F., Norregaard, C., Brener, M. & Sullivan, E. The budget impact of adding Pralsetinib to a US health plan formulary for treatment of non-small cell lung cancer and thyroid cancer with RET alterations. J. Managed Care Specialty Pharm. 28 (2), 218\u2013231 (2022).","journal-title":"J. Managed Care Specialty Pharm."},{"key":"17627_CR50","doi-asserted-by":"crossref","unstructured":"Woods, R. H. Dental Disorders Reported to the FDA Adverse Event Reporting System in Association with Buprenorphine: An Analysis by Ingredient Composition and Route of Administration. Current drug safety. (2023).","DOI":"10.2174\/1574886318666230731151447"},{"issue":"1","key":"17627_CR51","doi-asserted-by":"publisher","first-page":"12257","DOI":"10.1038\/s41598-023-39482-y","volume":"13","author":"Y Wang","year":"2023","unstructured":"Wang, Y. et al. Exploring the association between selective serotonin reuptake inhibitors and rhabdomyolysis risk basedon the FDA pharmacovigilance database. Sci. Rep. 13 (1), 12257 (2023).","journal-title":"Sci. Rep."},{"key":"17627_CR52","doi-asserted-by":"crossref","unstructured":"Zhao, H. et al. Major adverse cardiovascular events associated with testosterone treatment: a pharmacovigilance study of the FAERS database. Front. Pharmacol. ;14. (2023).","DOI":"10.3389\/fphar.2023.1182113"},{"key":"17627_CR53","doi-asserted-by":"crossref","unstructured":"Tang, L., Ding, C., Li, H., Zhou, X. & Yin, G. A Real-World disproportionality analysis of Drug-Induced immune hemolytic anemia in the FDA adverse event reporting system. (2023). The Annals of pharmacotherapy. :10600280231189897 -.","DOI":"10.1177\/10600280231189897"},{"key":"17627_CR54","doi-asserted-by":"publisher","first-page":"116632","DOI":"10.1016\/j.taap.2023.116632","volume":"475","author":"M Neishi","year":"2023","unstructured":"Neishi, M. et al. Structural characterization of the optical isomers Esomeprazole and Omeprazole using the JADER and FAERS databases. Toxicol. Appl. Pharmcol. 475, 116632 (2023).","journal-title":"Toxicol. Appl. Pharmcol."},{"issue":"6","key":"17627_CR55","first-page":"407","volume":"26","author":"L Zhu","year":"2023","unstructured":"Zhu, L. et al. Updated interpretation of the NCCN clinical practice guidelines (Version 3. 2023) for Non-small cell lung cancer. Zhongguo Fei Ai Za zhi\u2009=\u2009chinese. J. Lung Cancer. 26 (6), 407\u2013415 (2023).","journal-title":"J. Lung Cancer"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-17627-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-17627-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-17627-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T02:02:22Z","timestamp":1761962542000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-17627-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,27]]},"references-count":55,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["17627"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-17627-5","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,27]]},"assertion":[{"value":"11 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The research in this article does not involve the ethical part, and does not touch on animal experiments and human.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"37383"}}